Prediction of metastatic castrate-resistant prostate cancer response to abiraterone or enzalutamide by a baseline blood-based CTC gene expression signature

• Published in: Journal of clinical oncology Vol. 37; no. 15_suppl; p. e16529
• Main Authors: Lariviere, Michael Joseph, Haas, Naomi B., Cherkas, Yauheniya, Nielsen, Karl, Foulk, Brad, Patel, Jaymala, Smirnov, Denis, Vaughn, David J., Amaravadi, Ravi K., Savitch, Samantha L., Majmundar, Krishna, Buckingham, Thomas H., Yee, Stephanie S., Jones, Jeremy, Pal, Sumanta K., Carpenter, Erica L.
• Format: Journal Article
• Language: English
• Published: 20.05.2019

Abstract only e16529 Background: Prostate cancer is the most common cancer in men in the U.S., with 30% 5-year overall survival (OS) for patients (pts) with metastases. To take a precision medicine approach to the management of metastatic castrate-resistant prostate cancer (mCRPC), we developed a bl...